Capecitabine and docetaxel in advanced gastric adenocarcinoma, an ongoing phase II study

Peter Thuss‐Patience(Charité - Universitätsmedizin Berlin), Peter Reichardt(Helios Hospital Berlin-Buch), Andreas Loew(Helios Hospital Berlin-Buch), Daniel Pink(Universitätsmedizin Greifswald), B. Lebedinzew(Helios Hospital Bad Saarow), Bernd Dörken(Charité - Universitätsmedizin Berlin), S. Micheel(Klinikum St. Georg), Albrecht Kretzschmar(Roche (Switzerland)), Gero Massenkeil(Helios Hospital Berlin-Buch)
Journal of Clinical Oncology
June 1, 2005
10.1200/jco.2005.23.16_suppl.4224
Cited by 7

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells.
|Journal of Clinical Investigation|1997|765
Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|751